Regenerative medicine company commences reverse stock split — 5 insights

Cesca Therapeutics commenced a one-for-10 reverse stock split of its common stock June 4.

Advertisement

What you should know:

1. Cesca issued one share for every 10 outstanding shares absorbed.

2. The company will not change how many shares it’s authorized to issue.

3. Cesca authorized the reverse split to regain compliance with the Nasdaq’s $1 minimum bid price requirement.

4. Reverse stock splits typically help companies raise the price of their shares.

5. Cesca Therapeutics creates stem cell processing technologies and autologous cell-based therapies.

More articles on devices:
Zavation receives FDA approval for new spinal fusion device — 3 insights
Indiana device company receives FDA clearance for elbow system — 3 insights
Smith & Nephew acquires orthopedic joint reconstruction business — 4 insights

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.